{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:23:55Z","timestamp":1792567435761,"version":"4.5.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Male osteoporosis is increasingly recognized as a major public health issue. This multinational, 2-yr, randomized, double-blind, placebo-controlled study was conducted to determine the efficacy and safety of 35 mg once-a-week risedronate in men with osteoporosis. Patients had to be men \u226530 yr old, with lumbar spine T-score \u2264 \u22122.5 and femoral neck T-score \u2264 \u22121 SD or lumbar spine T-score \u2264 \u22121 and femoral neck T-score \u2264 \u22122 SD (based on young normal men). Patients were randomized 2:1 to risedronate 35 mg once a week or placebo for 2 yr; all patients took 1000 mg elemental calcium and 400\u2013500 IU vitamin D daily. Lumbar spine BMD at month 24 using last observation carried forward was the primary endpoint. Other endpoints included lumbar spine BMD at time points other than month 24, proximal femur BMD, bone turnover markers (BTMs), new vertebral fractures, clinical fractures, and adverse event (AE) assessment. There were 284 men enrolled in the study. Treatment with risedronate resulted in a significant increase from baseline to endpoint in lumbar spine BMD compared with placebo (4.5%; 95% CI: 3.5%, 5.6%; p &amp;lt; 0.001). Few new vertebral and nonvertebral fractures were reported, with no differences in fracture rates between the two groups. There was a significant (p &amp;lt; 0.01) reduction from baseline in BTMs for the risedronate group compared with placebo at all time points. No apparent differences in the pattern or distribution of AEs including serious and upper gastrointestinal AEs were observed. Risedronate therapy was well tolerated during this 2-yr study and was rapidly effective as indicated by significant BTM decreases at month 3 and BMD increases at month 6 (the earliest time points tested). The effects of risedronate treatment on BMD and BTMs in this study were similar to those previously shown to be associated with fracture risk reductions in women with postmenopausal osteoporosis.<\/jats:p>","DOI":"10.1359\/jbmr.081214","type":"journal-article","created":{"date-parts":[[2008,12,2]],"date-time":"2008-12-02T17:32:07Z","timestamp":1228239127000},"page":"719-725","source":"Crossref","is-referenced-by-count":164,"title":["Once-Weekly Risedronate in Men With Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double-Blind, Multicenter Study"],"prefix":"10.1093","volume":"24","author":[{"given":"Steven","family":"Boonen","sequence":"first","affiliation":[{"name":"University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S","family":"Orwoll","sequence":"additional","affiliation":[{"name":"Oregon Health & Sciences University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Wenderoth","sequence":"additional","affiliation":[{"name":"Procter & Gamble Pharmaceuticals, Schwalbach a. Ts, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen J","family":"Stoner","sequence":"additional","affiliation":[{"name":"Procter & Gamble Pharmaceuticals, Egham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle","family":"Eusebio","sequence":"additional","affiliation":[{"name":"Procter & Gamble Pharmaceuticals, Mason, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre D","family":"Delmas","sequence":"additional","affiliation":[{"name":"INSERM Research Unit 831 and University of Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024020320032478800_bib1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF01623184","article-title":"Hip fractures in the elderly: A world-wide projection","volume":"2","author":"Cooper","year":"1996","journal-title":"Osteoporos Int"},{"key":"2024020320032478800_bib2","author":"Seeman","year":"2009"},{"key":"2024020320032478800_bib3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1302\/0301-620X.80B2.0800243","article-title":"Epidemiology of fractures in 15,000 adults: The influence of age and gender","volume":"80","author":"Singer","year":"1998","journal-title":"J Bone Joint Surg Br"},{"key":"2024020320032478800_bib4","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","article-title":"Mortality after all major types of osteoporotic fracture in men and women: An observational study","volume":"353","author":"Center","year":"1999","journal-title":"Lancet"},{"key":"2024020320032478800_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s001980050197","article-title":"Survival after hip fracture: Short- and long-term excess mortality according to age and gender","volume":"10","author":"Fors\u00e9n","year":"1999","journal-title":"Osteoporos Int"},{"key":"2024020320032478800_bib6","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00223-001-1045-7","article-title":"Mortality, morbidity, and assessment of fracture risk in male osteoporosis","volume":"69","author":"Johnell","year":"2001","journal-title":"Calcif Tissue Int"},{"key":"2024020320032478800_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0889-857X(05)70186-1","article-title":"Osteoporosis in men","volume":"27","author":"Amin","year":"2001","journal-title":"Rheum Dis Clin North Am"},{"key":"2024020320032478800_bib8","first-page":"1521","article-title":"Osteoporosis in men","volume":"67","author":"Campion","year":"2003","journal-title":"Am Fam Physician"},{"key":"2024020320032478800_bib9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2024020320032478800_bib10","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"2024020320032478800_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"2024020320032478800_bib12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"2024020320032478800_bib13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00223-001-1060-8","article-title":"Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy","volume":"69","author":"Reid","year":"2001","journal-title":"Calcif Tissue Int"},{"key":"2024020320032478800_bib14","first-page":"178","article-title":"Recommendations for bone mineral density reporting in Canada","volume":"56","author":"Siminoski","year":"2005","journal-title":"Can Assoc Radiol J"},{"issue":"Suppl","key":"2024020320032478800_bib15","first-page":"S1","article-title":"Scientific Advisory Council of the Osteoporosis Society of Canada 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada","volume":"167","author":"Brown","year":"2002","journal-title":"CMAJ"},{"key":"2024020320032478800_bib16","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00223-001-1046-6","article-title":"Diagnosis of osteoporosis and fracture threshold in men","volume":"69","author":"Kanis","year":"2001","journal-title":"Calcif Tissue Int"},{"key":"2024020320032478800_bib17","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1359\/jbmr.2000.15.10.1867","article-title":"Assessing bone density in men","volume":"15","author":"Orwoll","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2024020320032478800_bib18","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2024020320032478800_bib19","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024020320032478800_bib20","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N Engl J Med"},{"key":"2024020320032478800_bib21","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00296-005-0004-4","article-title":"Efficacy of risedronate in men with primary and secondary osteoporosis: Results of a 1-year study","volume":"26","author":"Ringe","year":"2006","journal-title":"Rheumatol Int"},{"issue":"S1","key":"2024020320032478800_bib22","first-page":"S279","article-title":"Consistent 60% risk reduction of new vertebral fractures in men with osteoporosis after the first and second year of risedronate therapy","volume":"20","author":"Ringe","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2024020320032478800_bib23","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1001\/archinte.165.15.1743","article-title":"Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke","volume":"165","author":"Sato","year":"2005","journal-title":"Arch Intern Med"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.081214","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/24\/4\/719\/56576012\/5650240418.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/24\/4\/719\/56576012\/5650240418.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:51:49Z","timestamp":1710341509000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/24\/4\/719-725\/7599996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,1]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2009,4,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.081214","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,4,1]]},"published":{"date-parts":[[2009,4,1]]}}}